Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
about
Maraviroc: a review of its use in HIV infection and beyondThe CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1CYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.A comparative high-throughput screening protocol to identify entry inhibitors of enveloped virusesHypersensitivity reactions to HIV therapy.Clinical use of CCR5 inhibitors in HIV and beyondGLUE that sticks to HIV: a helix-grafted GLUE protein that selectively binds the HIV gp41 N-terminal helical region.An expedient synthesis of maraviroc (UK-427,857) via C-H functionalization.Decoding the chemokine network that links leukocytes with decidual cells and the trophoblast during early implantation.Treatment of HIV infection with the CCR5 antagonist maraviroc.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.Clinical utility of maraviroc.Drug safety evaluation of maraviroc for the treatment of HIV infection.The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.Coreceptor tropism determined by genotypic assay in HIV-1 circulating in Thailand, where CRF01_AE predominates.Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.Optimized dosing of a CCR2 antagonist for amplification of vaccine immunity.
P2860
Q26778504-B232834F-31B5-4BE5-B9B2-1569FA34AE8EQ33725916-2678541D-E8D9-4E2C-9B11-9ABF22A1927BQ34360012-4CEE77C4-F805-4976-BBB1-7D8B0A87EF87Q34791356-E6C9A154-6CE4-479F-B5CB-6845F22215C0Q34976463-718EAA5D-EEEE-40DB-ADE5-84980125C9C2Q35018145-4D47902A-903D-4808-9D82-9ACFA84DAA37Q35751518-CBE36A94-8325-4306-B099-42DCAC08394FQ35770826-EEF210C8-FD4B-4B86-A473-EC26FE7605DCQ36857976-3CD83F89-92ED-45A6-8A8D-78EBDBA00B66Q37733565-3909069E-16E9-4CB3-A491-F1E6FFFECDBFQ37845854-3AAD6630-132C-4860-A118-D15AF96FE679Q37877242-C195A0C0-9137-4B12-B2D8-DF0B0303B539Q37961188-266D90DA-C1E6-4C14-BE8D-9142B4D68724Q38714220-D86356B6-32D9-43E1-B094-40C91B70057BQ39074109-B4536393-F27F-469E-8E83-1DF70C76241DQ42256490-ACAF340A-9E2B-46D8-8265-5C9FA8A1195AQ42607941-6DE01593-51E2-4980-8A48-5E6101347CAEQ42771123-B09E9A42-3924-4EA8-91D5-46A74BEB4E89
P2860
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@ast
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@en
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@nl
type
label
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@ast
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@en
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@nl
prefLabel
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@ast
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@en
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@nl
P2093
P356
P1433
P1476
Pharmacokinetics, safety and t ...... d moderate hepatic impairment.
@en
P2093
Caroline E Ridgway
John D Davis
Julia C Hamlin
Manoli Vourvahis
Samantha Abel
P304
P356
10.3851/IMP1297
P577
2009-01-01T00:00:00Z